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ABSTRACT
The manipulation of dendritic cells (DCs) ex vivo to present tumor-associated antigens for the activation and
expansion of tumor-specific cytotoxic T lymphocytes (CTLs) attempts to exploit these cells’ pivotal role in
immunity. However, significant improvements are needed if this approach is to have wider clinical application.
We optimized a gene delivery protocol via electroporation for cord blood (CB) CD34 DCs using in
vitro–transcribed (IVT) mRNA. We achieved > 90% transfection of DCs with IVT-enhanced green fluores-
cent protein mRNA with > 90% viability. Electroporation of IVT-mRNA up-regulated DC costimulatory
molecules. DC processing and presentation of mRNA-encoded proteins, as major histocompatibility complex/
peptide complexes, was established by CTL assays using transfected DCs as targets. Along with this, we also
generated specific antileukemic CTLs using DCs electroporated with total RNA from the Nalm-6 leukemic
cell line and an acute lymphocytic leukemia xenograft. This significant improvement in DC transfection
represents an important step forward in the development of immunotherapy protocols for the treatment of
malignancy.
© 2006 American Society for Blood and Marrow Transplantation
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UNTRODUCTION
Interest in active and adoptive cellular immuno-
herapy to treat cancer has increased with recogni-
ion of the pivotal role of dendritic cells (DCs) in
he initiation of adaptive immune responses [1,2].
reparation of DCs to present speciﬁc tumor-asso-
iated antigens (TAAs) for phase I clinical trials
ave proven the safety of this approach, and some
imited but encouraging successes have been re-
orted [3-8]. These trials have reinforced the po-
ential for the immune system to target and eradi-
ate cancer using cytotoxic T lymphocyte (CTL)
upported by the New South Wales Cancer Council, Queensland Cancer
rund, and Mater Medical Research Institute.ffectors generated by autologous DC stimulation
ither in vivo or in vitro.
There are strong clinical incentives for reﬁning
C generation from CD34 hematopoietic progeni-
or cells, particularly from CBs, which are increasingly
eing used as a stem cell source in transplantation
iven their ready availability and the fact that out-
omes for CB transplant recipients compare favorably
ith those for matched sibling bone marrow trans-
lant recipients. The capacity to engineer DCs from
B is likely to play an increasingly important role in
trategies to promote a graft-versus-leukemia (GVL)
ffect in a manner analogous to the use of child/adult
onor leukocyte infusions after transplantation [9].
sing DCs to generate antileukemic CTLs to treatelapsed acute lymphoblastic leukemia (ALL) after
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A. K. W. Hsu et al.856ematopoietic stem cell transplantation (HSCT) is par-
icularly relevant, because most CB transplantations to
reat this disease are performed in children. With the
hift toward CB as a stem cell source for HSCT comes
he need to ensure that adoptive immunotherapy post-
SCT is feasible with CB-derived cells. We propose
hat anti-ALL CTL generated in vitro, administered
fter they have engrafted, is a potentially effective adop-
ive immunotherapy to prevent leukemic relapse.
RNA, as a source of antigen, is an efﬁcient way to
ntroduce antigens into DCs and is useful when the
arget is relatively nonimmunogenic, as in ALL. Elec-
roporation introduces RNA into Monocyte-derived
Cs (MoDCs) for the generation of antigen-speciﬁc
TLs [10-15]. Blood DCs also process and present
ntigen after electroporation with RNA. The electro-
oration settings used routinely kill a signiﬁcant pro-
ortion of DCs, and in those that survive, variable
ransfection efﬁciency may dramatically affect their
bility to process and present antigen. We therefore
ought to systematically optimize the RNA loading of
B CD34-derived DCs (CD34DCs) to generate
TLs.
Mature CB-derived CD34DCs were generated
nd reproducibly achieved  90% transfection efﬁ-
iency with in vitro–transcribed (IVT)-enhanced
reen ﬂuorescent protein (EGFP) mRNA while re-
aining  90% viability. We showed that electropo-
ation of mRNA up-regulated CD34DC costimula-
ory molecules and that the translated protein was
rocessed and presented in the context of major his-
ocompatibility complex (MHC) molecules. Using
otal RNA from the leukemic cell line Nalm-6 and an
LL xenograft, we were able to generate speciﬁc an-
ileukemic CTLs. Achievement of this high-level re-
roducible transfection efﬁciency and successful CTL
eneration represents an important step forward in
he development of clinical immunotherapy protocols
o treat ALL and other malignancies.
ATERIALS AND METHODS
ord Blood
The research ethics committees of the Mater
isericordiae Hospitals and University of New South
ales approved the use of human CB for research
urposes. CB samples were obtained after normal full-
erm delivery of babies with the mothers’ informed
onsent. CB was processed within 24 hours of collec-
ion.
B CD34 Stem Cell Isolation
CD34 cells were positively selected from the
ononuclear cell (MNC) fraction with MACS beads
Miltenyi Biotech), as described previously [16].
D34 hematopoietic progenitor cells and CD34 GNC fractions were cryopreserved and stored in liq-
id nitrogen.
eneration of CD34DCs
Cryopreserved puriﬁed CD34 cells were thawed
nd resuspended at 2  104 CD34 cells/mL in phe-
ol red-free, X-VIVO 15 serum-free medium (Cam-
rex) containing glutamine, penicillin, and streptomy-
in (Invitrogen) as base medium supplemented with
5 ng/mL of granulocyte macrophage colony-stimu-
ating factor (Novartis), 50 ng/mL of FLT3-L (Am-
en), 50 ng/mL of SCF (Amgen), 1 ng/mL of tumor
ecrosis factor- (R&D Systems), and 0.5 ng/mL of
ransforming growth factor- (R&D Systems). Half of
he cytokine medium was changed on days 5, 7, 9, and
1. Cells were harvested for electroporation studies on
ays 7 and 9.
low Cytometry
Phenotypic analysis of DCs after expansion in
ytokine medium was determined by ﬂow cytometry.
total of 10,000 events were routinely collected
n a FACS Calibur ﬂow cytometer (BD Biosciences,
an Jose, CA), and the results were analyzed with
ELLQuest (BD Biosciences) or FCS Express (De
ovo Software, Thornhill, Ontario, Canada). CD34
tem cell purity was determined with CD3 (ﬂuores-
ein isothiocyanate [FITC]), CD14 (Phycoerytherin
PE]), CD34 (PerCP-Cy5.5), and CD45 (Allophyco-
yanin [APC]) antibodies (BD Biosciences). Antibod-
es for DC phenotype analysis included CD1a, CD40,
D80, CD83 (all PE), CD11c (APC), HLA-DR
PerCP-Cy5.5), lineage markers (CD3, 14, 19, 20, and
6, all FITC), and isotype controls (mouse-IgG1
ITC, PE, PerCP-Cy5.5, and APC) (BD Bio-
ciences), CD86 (PE), CD15 and CD54 (FITC) (BD
iosciences or Immunotech), and BDCA-2 (CD123,
E) (Miltenyi). Cell viability was determined with
-AAD (Immunotech). HLA-A2 status of CB was de-
ermined using HB-B2 hybridoma supernatant and
heep anti-mouse immunoglobulin FITC (Chemi-
on).
For comparative experiments, when up-regulation
f DC activation markers was investigated, the in-
rease in mean ﬂuorescence index (MFI) was mea-
ured as a surrogate marker of antigen expression. The
ncrease in MFI was calculated by
old MFI (sample MFI isotype control MFI) ⁄
isotype control MFI.
lasmids
The vectors pGEM®4Z/FMP/64A encoding in-
uenza matrix protein (FMP) and pGEM®4Z/EGFP/
4A encoding EGFP were provided by Professor Eli
ilboa, Duke University Medical Center. Vectors
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RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 857ere linearized after overnight incubation with Sure-
ut buffer, water, and Spe I enzyme (Roche, Basel,
witzerland) at 37°C, followed by chloroform extrac-
ion. Linearized DNA was stored in Tris-EDTA
uffer (10 mM Tris Cl and 1 mM EDTA, pH 8)
t 70°C and used as required for IVT. The full-
ength human survivin cDNA (kindly provided by
rofessor Dario Altieri, University of Massachusetts
edical School) was subcloned into the HindIII/
amHI site of the pGEM-4Z vector (Promega, Mad-
son, WI). After large-scale ampliﬁcation and puriﬁ-
ation, the plasmid was linearized with BamHI and
sed as a template for IVT.
n Vitro Transcription of mRNA
A MEGAscript High-Yield Transcription Kit
Ambion, Austin, TX) was used for the IVT of sur-
ivin mRNA. During the reaction, the guanosine
riphosphate concentration was adjusted to 1.5 mM,
nd the cap analog m7G(5=) ppp (5=)G (Ambion) was
ncluded at 6 mM, with adenosine triphosphate, cyti-
ine triphosphate, and uridine triphosphate concen-
rations at 7.5 mM. Template DNA was digested with
Nase-free DNase I, and RNA was recovered by
iCl/ethanol precipitation. The RNA pellet was
ried in air, resuspended in sterile water, and incu-
ated for 30 minutes at 30°C in 20 mM of Tris.Cl
pH 7.0), 50 mM of KCl, 0.7 mM of MnCl2, 0.2 mM
f EDTA, 100 mg/mL of acetylated bovine serum
lbumin, 10% glycerol, 1 mM of adenosine triphos-
hate, and 5,000 U/mL of yeast poly(A) polymerase
USB, Cleveland, OH). The capped, polyadenylated
NA was recovered as described earlier, quantiﬁed,
nd stored at 80°C.
Transcription of EGFP- and FMP-linearized
NA was performed using the mMessage mMachine
7 kit (Ambion) according to the manufacturer’s in-
tructions to generate IVT-mRNA. mRNA puriﬁca-
ion was performed by elution using the MEGAclear
it (Ambion). RNA concentration was calculated by
pectrophotometry, and the quality and size were
hecked by gel electrophoresis. IVT-mRNA was
tored in aliquots at 70°C.
otal RNA Extraction
Total RNA from the Nalm-6 cell line and an ALL
enograft (grown in NOD-SCID mice exactly as de-
cribed previously [17]) was extracted using the Qia-
en RNeasy Midi kit (Qiagen, Hilden, Germany),
ccording to the manufacturer’s instructions. A total
f 108 cells were lysed and homogenized. Ethanol was
dded to promote binding of RNA to the RNeasy
ilica gel membrane, and the sample was washed. The
uality and quantity of RNA were determined by
pectrophotometry and gel electrophoresis. Total
NA was stored at 70°C. Transfection Protocols
CD34 hematopoietic progenitor cells (HPC)
ultures were harvested on days 7 or 9 (as speciﬁed in
he text) and centrifuged to remove the cytokine me-
ium before being resuspended in electroporation
edium and subjected to electroporation in 200-L
uvettes in a Gene Pulser II (BioRad, Hercules, CA).
ptimization experiments investigated the following
ariables: range of voltage (50–350 V), range of ca-
acitance (75-150 F), electroporation medium (X-
IVO 15, RPMI medium 1640 and Opti-MEM [In-
itrogen, San Diego, CA), incubation of cells before
10 minutes) and after electroporation (0–30 minutes)
t varying temperatures (37°C, ice, room tempera-
ure), mRNA concentration (2–16 g), and cell con-
entration (1–20  106/mL). EGFP expression and
ell viability were determined by ﬂow cytometry per-
ormed 24 hours postelectroporation after cells were
tained with 7-AAD for viability and HLA-DR and
D11c for CD34DC. Transfection efﬁciency was
valuated in total cell and DC subpopulations.
TL Generation
HLA-A2 DCs were electroporated on day 9 of
ulture with 20 g of Nalm-6 total RNA or 20 g of
otal RNA ALL-19 xenograft or 8 g of survivin IVT-
NA per 1  106 cells. Then, 12 hours after transfec-
ion, autologous CD34 MNCs were primed with
ransfected DCs at 2 106 MNCs: 2 105 DCs/well in
-Vivo 15 medium supplemented with 25 U of inter-
eukin (IL)-2/mL (Roche) and 25 ng of IL-7/mL (Pep-
oTech, Rocky Hill, NJ). Fresh medium and 25 U/mL
f IL-2 and 25 ng/mL of IL-7 were added every 3 days.
he remaining transfected DCs were cryopreserved for
estimulation. At restimulation, autologous transfected
Cs were thawed and used as stimulators at an Effector:
arget (E:T) ratio of 10:1. A chromium release assay was
erformed every 7 days.
1Chromium Release Assay
A standard 4-hour 51Cr assay was performed to
ssess the speciﬁcity of CTLs. Target cells were
ashed in RPMI-1640 with 10% fetal calf serum and
abeled with 100 C 51Cr (Amersham BioSciences,
iscataway, NJ) for 1 hour at 37°C. Effector cells were
repared in RPMI-1640 with 10% fetal calf serum.
he ﬁnal volume of effectors and targets was 100 L
n 96-well V-well plates with appropriate controls for
pontaneous and maximum release of 51Cr. K562
ells were included as cold targets to remove natural
iller cell killing. After 4 hours of incubation at
7°C, the plates were centrifuged, and 50 L of
upernatant was harvested and added to the Optimix
OptiPhase Supermix, Wallac, Finland) scintillation
uid. 51Cr release was read on a Wallac MicroBeta
riLux liquid scintillation and luminescence counter
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A. K. W. Hsu et al.858PerkinElmer, Boston, MA). Speciﬁc lysis was calcu-
ated according to the following standard formula:
specific lysis(counts in test well
 counts in spontaneous wells) ⁄
(counts in maximum lysis well
igure 1. Characterization of CB-derived DCs. (A) Subset analysis
hen staining for HLA-DR and CD11c. The cells could then be sub
ells in the upper left quadrant (DR11c) were designated precurs
esignated non-DCs. The next 4 panels show that the cultures we
D34 negative. (B) The DR/11c phenotype of the culture was ana
CD40, CD54, CD80, CD83, and CD86) on all 3 populations ove counts in spontaneous wells)100 Atatistical Analysis
Systat 10.2 software (Hearne Scientiﬁc, Mel-
ourne, Australia) was used for experimental design
nd analysis. All experiments were repeated at least 3
imes, and results are expressed as mean  standard
rror of the mean. Results were signiﬁcant at P  .05.
cultures on day 9 followed initial gating on the live cell gate (R1),
to identify the DC subset in the upper right quadrant (DR11c).
mature DCs, and those in the lower left quadrant (DR11c) were
A2, CD16, lineage (CD3, CD14, CD19, CD20, and CD56), and
ver time. (C) Expression of costimulatory and activation markers
e course from day 7 to day 10.of cell
divided
or or im
re BDC
lyzed onalysis of variance (ANOVA) and post hoc Bonfer-
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RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 859oni tests were used to determine the optimal cytokine
ombination to generate DCs and to identify which
lectroporation variables had a signiﬁcant effect on
GFP expression and cell survival.
ESULTS
eneration of CD34DCs
CD34 expression was lost by day 7 of culture,
nd the cultured cells lacked lineage marker expres-
ion (CD3, CD14, CD19, CD20, and CD56) as well
s the CD16, CD123, and BDCA2 antigens (Figure
A). Most of these CD34DC preparations have
he phenotypic characteristics of DCs (HLA-DR
D11cLin). Differential expression of CD11c and
LA-DR by the CD34DCs enabled discrimination
f 3 distinct populations, designated as precursor or
mmature DCs (CD11chiHLA-DRlow), mature DCs
CD11chiHLA-DRhi), or non-DCs (CD11cHLA-
R) (Figure 1B). Total cell counts (50  5 total cells
er CD34-initiating cell at day 7 [n 	 10] and 62  6
otal cells per CD34-initiating cell at day 9, [n 	 22])
ndicated a major increase in total cell number by day 7
ut a slower rate of expansion thereafter. A single
D34-initiating cell gave rise to 19 3.9 CD34DCs
Figure 1n 	 8) by day 7 of culture and 40  1.8 CD34DCs cn	 12) by day 9 of culture. Subset analysis of activation
nd costimulatory molecules known to effect DC func-
ion (CD40, CD54, CD80, CD83, and CD86) re-
ealed that non-DC and immature/precursor pop-
lations expressed lower levels than the mature DC
ubset. Evaluation of their expression patterns on
ays 7–10 of culture showed that peak expression
ccurred on day 9 in the mature DC subset (Figure
C). These ﬁndings provided a rational basis for
erforming most electroporation experiments on
D34DCs on day 9.
reliminary Transfections
Electroporation parameters commonly used for
oDCs (300–350 V and 100–150 F) [10,11,13,
4,18] were used to determine whether these condi-
ions could be translated to CD34DCs on days 7 and
of culture. Using these conditions, we achieved only
0%  5% (n 	 5) EGFP transfection efﬁciency of
he DC subset with poor viability (20%  1.5%; n 	
). Light microscopy revealed extensive cell damage as
oon as 6 hours after electroporation; therefore, we
xamined the key variables in the electroporation pro-
ocol in an effort to improve both transfection efﬁ-
tinued)iency and cell viability.
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A. K. W. Hsu et al.860lectroporation Voltage and Capacitance
Day 9 CD34DC cultures were electroporated
ith EGFP IVT-mRNA in X-VIVO 15 medium over
range of voltages (50–350 V) and capacitances (75–
50 F) and incubated on ice for 1 minute before
eing returned to cytokine-containing medium. In-
reasing the electroporation settings resulted in
reater cell death with low to moderate transfection
fﬁciency, whereas reducing these settings produced
reater cell viability, but also lower transfection efﬁ-
iency (Figure 2). Light microscopy examination of
D34DCs revealed extensive cellular damage and
ebris at higher settings (350 V; 125 F) than at lower
ettings (250 V; 100 F). These experiments also
howed an electromagnetic membrane permeation
hreshold of 100 V for CD34DCs, with virtually
o EGFP expression below this voltage. Above this
hreshold, a range of settings (250–300 V with 75–
00 F) resulted in greater EGFP expression with
oderate cell survival. The next step was to improve
C transfection efﬁciency and viability by investigat-
ng the effect of other parameters likely to affect cell
ntegrity.
lectroporation Media, Incubation,
nd Temperature
Cell survival and transfection efﬁciency were com-
ared for cells electroporated in X-VIVO 15, RPMI-
640, and Opti-MEM media at 300 V and 125 F. A
reliminary matrix experiment demonstrated that cells
lectroporated in RPMI-1640 had higher EGFP
ransfection efﬁciency. Viability decreased with pro-
onged incubation on ice after electroporation regard-
igure 2. Transfection efﬁciency and viability of DCs over a ran
arvested on day 9 and transfected in X-Vivo 15 with 4 g of IVT
anged from 75 to 150 F. Flow cytometric analysis was performed
C population. The graph shows the percentage of viable DCs (bess of the media used (Figure 3A). The time constants eie, the time [in seconds] for the initial electromag-
etic pulse to decay to 63% of its initial ﬁeld strength)
ecorded for these electroporation events were highly
onsistent for each medium (RPMI-1640: 1.96  0.06
econds; X-VIVO 15, 2.35  0.06 seconds; Opti-
EM, 2.28  0.03 seconds; n 	 12). ANOVA con-
rmed that media had a signiﬁcant effect on the elec-
roporation time constant (P 
 .001), suggesting that
lower time constant had a positive effect on cell
urvival. Post hoc Bonferroni tests revealed that the
PMI-1640 medium permitted the greatest cell sur-
ival (P 	 .02), although recovery was still less than
esirable. In subsequent experiments, RPMI-1640 was
sed as the medium for electroporation. Lower volt-
ge and capacitance settings (250 V and 100 F) were
lso applied to maximize cell viability.
We investigated how maintaining cells at a speciﬁc
emperature before or after electroporation affected
ell survival and transfection efﬁciency. Prolonged in-
ubation at low temperature after electroporation re-
ulted in a drop in viability compared with incubation
t room temperature (Figure 3B). The inclusion of an
dditional 10-minute incubation at 37°C before elec-
roporation, followed by 5 minutes at room tempera-
ure after electroporation, further improved viability
 90%; P 	 .026 for preincubation at 37°C and P 	
025 for postelectroporation at room temperature)
Figure 3C).
RNA and Cell Concentration and Time Course
f mRNA Expression
Ideally, all cells should be equally exposed to the
voltage and capacitance settings. CD34 stem cell cultures were
P mRNA. The voltage ranged from 50 to 350 V, and capacitance
urs postelectroporation using HLA-DR and CD11c to identify the
) and the percentage of viable DCs expressing EGFP (white bar).ge of
-EGF
24 holectrical ﬁeld to achieve maximum mRNA uptake.
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RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 861igure 3. The effect of electroporation medium, incubation time, and temperature on transfection efﬁciency and cell survival. (A) CD34
tem cell cultures were harvested and electroporated (at 300 V and 125 F) on day 9 of culture in RPMI-1640, Opti-MEM, or X-VIVO
5 with 4 g of IVT-EGFP mRNA. Electroporated cells were then incubated in the electroporation medium (either RPMI-1640,
pti-MEM, or X-VIVO 15) for up to 10 minutes on ice before being returned to the cytokine culturing medium. Viability (7-AAD
xclusion) and EGFP expression were assessed by ﬂow cytometry 24 hours later. (B) Cells were electroporated under the same conditions
ust described (in RPMI-1640), except the cells were incubated postelectroporation for up to 10 minutes at room temperature or on ice,
nd viability was assessed by 7-AAD exclusion. (C) Cells were incubated either at 37°C, on ice or at room temperature for 10 minutes
efore electroporation. After electroporation, cells were incubated for a further 5 minutes at room temperature before being returned
o the cytokine culturing medium.
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A. K. W. Hsu et al.862e performed a matrix experiment comparing the
ffect of mRNA concentrations and cell numbers on
ransfection efﬁciency using optimal settings and
onditions. Cell concentrations of 5  106/mL and
0  106/mL had the highest transfection efﬁciencies
Figure 4A), but all cell preparations had viability 
0% (data not shown). Increasing mRNA concentra-
ion had a signiﬁcant effect on the proportion of
igure 4.The effect of varying RNA and cell concentration on trans
n DC costimualtory capacity. CD34 cells were harvested on day 9
GFP expression were analyzed 24 hours postelectroporation. (A)
g of IVT-EGFP. (B) Fold-MFI analysis of EGFP expression of DC
to 16 g. (C) Using the same settings as before, 5  106/mL of
nalyzed over a time course. (D) Effect of electroporation and RNA
and electroporated with patient ALL total RNA. Over 24 hours,GFP cells within the whole cell population tANOVA; P
 .001). The DC population appeared to
e selectively targeted and reached a maximum trans-
ection efﬁciency plateau at 4–8 g (data not shown);
owever, MFI analysis of these DCs at 5  106/mL
nd 10  106/mL showed that increasing mRNA
oncentration correlated with increased EGFP pro-
ein production (ANOVA; P 	 .001) (Figure 4B).
We examined EGFP expression over an extended
efﬁciency and time analysis of EGFP expression, and effect of RNA
ectroporated at 250 V and 100 F in RPMI-1640. DC viability and
concentrations of 1–20  106/mL were electroporated with 2–16
oporated at 5 or 10  106/mL, with mRNA amounts ranging from
re electroporated on days 7 and 9, and DC EGFP expression was
costimulatory capacity. CD34 cell cultures were harvested on day
CD40, CD80, and CD86 were analyzed.fection
and el
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RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 863ffect on downstream in vitro and in vivo CTL gen-
ration. Using the same parameters (5  106 cells/mL
nd 4 g mRNA), we performed a 24-hour EGFP
eadout for cells electroporated on days 7 and 9.
GFP expression was readily detected 3 hours after
lectroporation and peaked at around 12 hours for
oth day 7 and 9 CD34DCs (Figure 4C).
Because our clinical goal was to generate antileu-
emic CTLs from leukemic RNA-loaded CD34DC,
e monitored the up-regulation of CD1a, CD40,
D80, and CD83 expression by CD34DCs after elec-
roporation with total RNA derived from a patient ALL
enograft. CD34DC expression of CD1a, CD40,
D80, and CD83 was up-regulated and reached a
lateau at or after 16–20 hours postelectroporation
ompared with nonelectroporated DCs (Figure 4D).
he expression of CD86 remained high (in  90% of
D34DCs) regardless of electroporation; thus, we
etermined that incubation for 12 hours would max-
mize antigen processing and presentation by electro-
orated CD34DCs before co-culturing with T cells
or CTL induction.
ptimized Transfection Protocol
We compared transfection efﬁciencies obtained
fter optimizing the procedure with those obtained
ith the starting conditions derived from the litera-
ure (Figure 5). We found that up to 96% (92.32% 
igure 5. Comparison of nonoptimized and optimized electropo-
ation conditions. Comparison of transfection efﬁciency and cell
iability (24 hours postelectroporation) of CD34 stem cell–de-
ived DCs before and after optimization. (A) Electroporation using
onoptimized conditions (300 V, 125 F) followed by 1 minute of
ncubation on ice. (B) Electroporation with the following parame-
ers: preincubation of 5  106 cells at 37°C for 10 minutes, 250 V,
00 F, electroporation in RPMI-1640 with 4 g of IVT-EGFP,encubation at room temperature for 5 minutes postelectroporation..73%; n	 6) transfection efﬁciency, accompanied by
igh viability ( 93%), was achievable in CD34DCs
sing our optimized protocol. Thus, when using 5 
06 total CD34DCs for electroporation, we would
xpect to obtain 2.5  106 live EGFP CD34DCs,
hich is sufﬁcient to stimulate 25  106 MNCs for
TL induction and produce 100  106-expanded
TLs by 2 weeks. These electroporation conditions
ave also been tested on BDCA-1 blood DCs with
imilar results (data not shown).
resentation of Peptides on CD34DCs in the
ontext of MHC Molecules
To conﬁrm that transfected mRNA was translated
nd the protein was processed and presented as pep-
ides in the context of MHC molecules by the
D34DC, we examined the susceptibility of day 9
MP-mRNA transfected CD34DCs as CTL targets
or HLA-A201–matched FMP-speciﬁc T-cell clones
E:T ratio of 10:1). FMP-mRNA was translated and
resented on the MHC, as evidenced by speciﬁc CTL
ysis (54%  8%; n 	 3) of day 9 FMP-RNA–loaded
D34DCs (Figure 6). The addition of polyinosine-
olycytidylic acid (poly I:C) as a DC maturation agent
nduced only a marginal further increase in speciﬁc
ysis (58%  6%; n 	 3), consistent with our pheno-
ypic data suggesting that CD34DCs already express
ctivation and costimulatory molecules (Figure 1C).
eneration of Antileukemic CTLs
Day 9 CD34DCs from 3 HLA-A2 CB donors
ere electroporated with Nalm-6 total RNA to gen-
igure 6. Presentation of FMP peptides. CD34 HSC culture was
arvested on day 9 and transfected with IVT-FMP (Flu) mRNA
nder the optimized conditions. Then, 24 hours after electroporation,
ells were labeled with 51Cr for use as targets in CTL assays. Effectors
ere FMP-T cell clones (speciﬁc for epitope GILVFTFTL), and the
:T ratio was 10:1. Targets were nonelectroporated (NE) controls,
lectroporated cells without FMP electroporated control (EC), T2
ontrols, FMP-transfected cells, and FMP-transfected DCs with the
ddition of Poly I:C for 24 hours. 51Cr release was measured.rate bulk CTL cultures. After 1 antigenic restimula-
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A. K. W. Hsu et al.864ion, the CTLs speciﬁcally lysed Nalm-6 targets at
8%  11% at an E:T ratio of 50:1, compared with
.5%  1.3% for autologous MNCs (P 	 .03) and
.5%  1.2% for allogeneic HLA-A2 MNCs (P 	
022) (Figure 7A).
CTLs generated using this system also recognized
rimary leukemia cells. Total RNA derived from an
LA-A2 patient ALL xenograft that had been ex-
anded and extracted from NOD-SCID mice [23]
ere used to load HLA-A2 CD34DCs. After a single
ntigenic restimulation, the anti-ALL xenograft CTLs
igure 7. CTLs generated from total RNA electroporated DCs are
ere harvested on day 9 of culture and electroporated with Nalm-6
nd 51Cr release assays were conducted after the ﬁrst restimulatio
argets used were Nalm-6 and autologous and allogeneic MNCs (
utologous, P 	 .029; to allogeneic, P 	 .021). (B) A2 DCs from
he targets used were autologous MNCs, Nalm-6, and autologous A
fter priming and after the ﬁrst restimulation.ysed 63% 6% of the ALL xenograft cells, compared lith 22%  7% of autologous MNCs (P 
 .001)
Figure 7B). The bulk CTL culture consisted of CD4
68%  1.8%) and CD8 (12.6%  1.4%) T cells,
hich increased in number after a single in vitro
estimulation, with the population of natural killer
ells remaining at 
 10% (Figure 7C). Interestingly,
hese CTLs also retained their capacity to lyse the
LA-A2–matched Nalm-6 cell line (P 
 .001).
e also tested whether these anti-ALL xenograft
TLs were able to target generic proteins such as
urvivin (an inhibitor of apoptosis expressed in both
speciﬁcally lyse leukemia targets. (A) HLA-A2DCs from 3 donors
NA. Autologous MNCs were primed with the electroporated DCs,
thawed autologous DC electroporated with Nalm-6 total RNA.
TL to autologous, P 	 .03; to allogeneic, P 	 .022; 25:1 CTL to
rs were used to generate bulk CTLs with patient ALL total RNA.
) Phenotype of bulk cultures (CD3, CD4, CD8, and CD56) 1 weekable to
total R
n with
50:1 C
2 dono
LL. (Ceukemia and solid tumors [19]) by using autologous
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RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 865D34DCs electroporated with IVT-survivin mRNA
s targets in the 51Cr CTL assay. Here 16%  5.4%
f survivin mRNA electroporated CD34DCs were
ysed, compared with only 5%-7% of nonelectropo-
ated DCs (data not shown). These observations sug-
est that using our optimized electroporation proto-
ol, RNA-loaded CD34DCs are capable of generating
ntileukemic CTLs that speciﬁcally recognize leukemic
ells and generic tumor-associated antigens.
ISCUSSION
Strategies that use DC-mediated induction of
ntigen-speciﬁc effector CTLs to promote a GVL
ffect posttransplantation may improve outcomes for
atients undergoing transplantation for acute leuke-
ia. Current strategies to treat leukemic relapse have
sed donor leukocyte infusions and second transplan-
ation with limited success [20,21]. For DC-based
mmunotherapy to be effective in the posttransplan-
ation setting, there must be reliable protocols for
enerating functional DCs from the transplant prod-
ct and a reproducible and safe method for introduc-
ng TAAs into DCs. The increased use of CB as a
ransplant stem cell source has prompted us to develop
nd optimize protocols for the production of immu-
otherapy tools—namely DC and antigen-loading
rocedures—from CB CD34 cells. As a result, we
ave generated CB-derived CD34DCs that, when
lectroporated with leukemic RNA, stimulate the gen-
ration of antileukemic CTLs.
Successful electroporation of mRNA has been
eported in monocyte-derived DCs (30%–60%)
10,14,15,22], bone marrow CD34-derived DCs
72%) [15, 22], Langerhans cells (53%) [15, 22], and
eripheral blood CD34-derived DCs (89%) [23].
uccessful electroporation of CB-derived DCs (70%–
0%) also has been reported [24,25], but these studies
sed serum to generate the DCs. A number of these
eports do not discuss cell viability after electropora-
ion, and in those that do, the range is between 40%
nd 90% [15,22,23]. Our ﬁndings represent a signiﬁ-
ant step forward, because our CD34DC culture
ystem is serum-free, and the optimized electropora-
ion protocol results in consistently high transfection
fﬁciency and viability.
Electroporation carries an inherent risk of irre-
ersibly damaging the cell membrane and possibly
illing the cell. A balance between the extent of pore
ormation, transfection efﬁciency, and the cell’s ability
o recover after transfection must be established. Pore
ormation depends directly on the strength of the
pplied voltage and capacitance, because it is respon-
ible for the level and magnitude of cell membrane
isruption that allows the entry of macromolecules
nto cells [26,27]. Increasing these settings correlated rith higher transfection efﬁciency and lower cell vi-
bility. Our optimal settings (250 V and 100 F) are
ower than the conditions used for MoDCs. A pos-
ible explanation for this is that cell size determines
he minimal electrical ﬁeld strength required to per-
eate cell membranes, according to the formula
 Vc ⁄1.5A, where E is the electrical ﬁeld strength,
c is the critical breakdown voltage, and A is the cell
adius [26,28]. The media supporting the cells during
lectroporation affects the conductivity of the electro-
agnetic pulse, with its impact reﬂected in the time
onstant. A higher time constant implies that the applied
ulse decays at a slower rate, exposing cells to the applied
ulse for longer periods and possibly resulting in greater
amage. The medium with the lowest time constant
RPMI-1640) produced the highest CD34DC survival.
ncubating electroporated cells on ice caused unac-
eptably high cell death, probably by reducing cell
etabolism and hence impairing cell repair. Thus,
arming cells before electroporation at 37°C and in-
ubating them at room temperature after electropo-
ation can further improve transfection efﬁciency and
iability.
Cell concentrations used for electroporation vary
reatly (1–50  106/mL) [18,24,25,29]. We showed
hat CD34DCs can be electroporated effectively at
–20  106/mL, and that electroporation at higher
ell concentrations in a clinical setting will be more
fﬁcient and more compatible with clinical Good
anufacturing Practice (GMP) procedures. Notably,
D34DCs were transfected preferentially. Increas-
ng mRNA concentration had a minimal effect on the
ercentage of EGFP CD34DCs. Similar results
ere found in our human blood DC experiments
Turtle et al) and mouse bone marrow DCs [11].
owever, increasing mRNA concentration increased
he amount of translated protein, which may necessi-
ate further titration to optimize individual high-avid-
ty TAA-speciﬁc CTL generation. We anticipate ﬁnd-
ng that CD34DCs, which express transfected
RNA at peak levels, are more desirable for CTL
nduction. In our 24-hour time course, EGFP expres-
ion occurred rapidly (within 3 hours of transfection),
eaking after 12 hours regardless of the day on which
he CD34DCs were transfected. This ongoing ex-
ression augurs well for CD34DC functionality after
njection and migration in the patient. A time course
erformed by Van Meirvenne et al [11] using bone
arrow–derived DCs showed no peak expression over
6 hours, whereas Ueno et al [23] reported that EGFP
xpression in adult CD34DCs was still readily de-
ectable 24 hours after electroporation, but declined
radually thereafter. The method used to generate
D34DCs from CB is equally efﬁcient when gener-
ting CD34DCs from bone marrow and mobilized
eripheral blood (data not shown), but further work is
equired to establish whether these differences in RNA
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A. K. W. Hsu et al.866xpression reﬂect physiological differences between dif-
erent types of DC preparations.
Electroporation in the presence of RNA led to
ppropriate induction of costimulatory molecules,
ossibly due to RNA-induced toll-like receptor (TLR)
ctivation of CD34DCs [30]. The ability of trans-
ected DCs to present translated mRNA in the context
f MHC for recognition by T cells is crucial for CTL
nduction. After electroporation with IVT-FMP
RNA, CD34DCs translate and present peptides, as
videnced by the speciﬁc recognition and lysis of
MP-expressing CD34DCs by the FMP T-cell
lones. Most importantly, we generated antileukemic
TLs using total RNA derived from both Nalm-6
nd a patient ALL xenograft [17]. The resultant CTLs
ere able to lyse the leukemia targets speciﬁcally. This
emonstrates the potential efﬁcacy and safety of total
eukemic cell RNA in stimulating antileukemic re-
ponses.
Only 1 antigenic restimulation was required to
enerate a strong antileukemic response for the ALL
ell line and the patient’s ALL xenograft. This success
ompared with other approaches may relate to the
eterogenous nature of our CD34DC preparation or
o the use of improved electroporation conditions that
llow more efﬁcient gene delivery and hence more
fﬁcient translation and presentation of peptides. Fur-
hermore, the CD34DCs are highly activated with
ncreased expression of costimulatory markers only
fter electroporation with RNA, which means that the
D34DCs are fully activated when they encounter
he T cells. Using total RNA as the antigen source has
dvantages as well, including a potentially greater ca-
acity to activate TLRs [30], and thereby DC-medi-
ted CTL induction, and also to present a wide variety
f known and unknown TAAs, which may increase
arget cell lysis.
Poor immune reconstitution and the potentially
imited period before early leukemic relapse after CB
SCT makes active donor DC vaccination to gener-
te an in vivo anti-ALL CTL response a difﬁcult
rospect. We propose that CD34DCs may be used
o generate anti-ALL speciﬁc CTLs in vitro for sub-
equent passive immunotherapy posttransplantation.
owever, adoptive immunotherapy using total RNA
s the source of leukemic antigen may be a double-
dged sword, with the potential for generating CTLs
gainst known and unknown TAAs but also the po-
ential to generate alloreactive CTLs and induce
VHD. Survivin is an antiapoptotic protein expressed
n leukemia and other malignancies [19], and the use
f speciﬁc survivin mRNA or other leukemia TAAs
ay become a more deﬁned posttransplantation im-
unotherapy strategy. For this reason, we included
urvivin as a target and showed that anti-ALL xeno-
raft CTLs were able to lyse survivin-loaded
D34DCs. These observations suggest that survivins a valid target antigen for ALL and that the DC
ulture and electroporation protocol generates a poly-
lonal antileukemic CTL population that preferen-
ially recognizes leukemic cells. These results suggest
hat our CD34DC-mediated antileukemic CTLs are
ore likely to induce a GVL effect as opposed to a
VHD effect.
In summary, we have deﬁned conditions for the
ery effective RNA transfection of CD34DCs to
enerate antileukemic CTL activity. Current work is
ocusing on testing the in vivo efﬁcacy of CD34DC-
ediated antileukemic CTLs in a NOD-SCID mouse
odel of primary human leukemia. These data will
ave the way for the ﬁrst phase I clinical trials of
ost-CB transplantation immunotherapy to treat leu-
emia relapse [31,32,33,34,35].
CKNOWLEDGMENTS
Andy Hsu and Dr. Beverley Kerr performed all of
he electroporation experiments, dendritic cell pheno-
yping, and CTL assays, as well as the relevant data
nalysis, and assisted with drafting the manuscript. Dr.
athryn Jones optimized production of cord blood
D34-derived dendritic cells. Dr. Richard Lock
roduced the Survivin IVT-RNA and the acute lym-
hocytic leukemia xenograft. Professor Derek Hart
rovided critical feedback in the writing of the manu-
cript. Dr. Alison Rice was responsible for the con-
eptual and experimental design of the project, data
nalysis and interpretation, and manuscript prepara-
ion.
The authors thank Dr. Masato Kato and Dr.
ameron Turtle of the Mater Medical Research In-
titute for providing equipment, reagents, and assis-
ance with molecular protocols and Dr. Eli Gilboa of
uke University for providing the EGFP and FMP
ectors. The Children’s Cancer Institute Australia for
edical Research is afﬁliated with the University of
ew South Wales and Sydney Children’s Hospital.
he Mater Medical Research Institute is afﬁliated
ith the University of Queensland.
EFERENCES
1. Hart DN. Dendritic cells: unique leukocyte populations which
control the primary immune response. Blood. 1997;90:3245-
3287.
2. Hart DN, Hill GR. Dendritic cell immunotherapy for cancer:
application to low-grade lymphoma and multiple myeloma.
Immunol Cell Biol. 1999;77:451-459.
3. O’Rourke MG, Johnson M, Lanagan C, et al. Durable com-
plete clinical responses in a phase I/II trial using an autologous
melanoma cell/dendritic cell vaccine. Cancer Immunol Immu-
nother. 2003;52:387-395.
4. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of
peptide-pulsed mature dendritic cell vaccines results in superior
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells 867CD8 T-cell function in melanoma patients. J Clin Oncol.
2003;21:3826-3835.
5. Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with
p53-peptide-pulsed dendritic cells, of patients with advanced
breast cancer: report from a phase I study. Cancer Immunol
Immunother. 2004;53:633-641.
6. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-
pulsed dendritic cells elicits antigen-speciﬁc, cytotoxic T-cells
in patients with malignant glioma. Cancer Res. 2004;64:4973-
4979.
7. Iwashita Y, Tahara K, Goto S, et al. (2003) A phase I study of
autologous dendritic cell–based immunotherapy for patients
with unresectable primary liver cancer. Cancer Immunol Immu-
nother. 2003;52:155-161.
8. Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic
cells fused with tumor cells: preclinical results and outcome of
a clinical phase I/II trial in patients with metastatic renal cell
carcinoma. Hum Gene Ther. 2003;14:483-494.
9. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat he-
matologic malignancies in relapse after allogeneic blood or
marrow transplantation. Cancer Control. 2002;9:123-137.
0. Kalady MF, Onaitis MW, Padilla KM, et al. Enhanced den-
dritic cell antigen presentation in RNA-based immunotherapy.
J Surg Res. 2002;105:17-24.
1. Van Meirvenne S, Straetman L, Heirman C, et al. Efﬁcient
genetic modiﬁcation of murine dendritic cells by electropora-
tion with mRNA. Cancer Gene Ther. 2002;9:787-797.
2. Ponsaerts P, Van Tendeloo VF, Cools N, et al. mRNA-elec-
troporated mature dendritic cells retain transgene expression,
phenotypical properties and stimulatory capacity after cryo-
preservation. Leukemia. 2002;16:1324-1330.
3. Milazzo C, Reichardt VL, Muller MR, et al. Induction of
myeloma-speciﬁc cytotoxic T cells using dendritic cells trans-
fected with tumor-derived RNA. Blood. 2003;101:977-982.
4. Grunebach F, Muller MR, Nencioni A, et al. Delivery of
tumor-derived RNA for the induction of cytotoxic T-lympho-
cytes. Gene Ther. 2003;10:367-374.
5. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. (2001) Highly
efﬁcient gene delivery by mRNA electroporation in human
hematopoietic cells: superiority to lipofection and passive puls-
ing of mRNA and to electroporation of plasmid cDNA for
tumor antigen loading of dendritic cells. Blood. 2001;98:49-56.
6. Case J, Rice A, Vowels M. Conditions affecting the isolation of
human umbilical cord blood CD34 cells. J Hematother. 1996;
5:255-260.
7. Lock RB, Liem N, Farnsworth ML, et al. The nonobese
diabetic/severe combined immunodeﬁcient (NOD/SCID)
mouse model of childhood acute lymphoblastic leukemia re-
veals intrinsic differences in biologic characteristics at diagnosis
and relapse. Blood. 2002;99:4100-4108.
8. Ponsaerts P, Van den Bosch G, Cools N, et al. Messenger RNA
electroporation of human monocytes, followed by rapid in vitro
differentiation, leads to highly stimulatory antigen-loaded ma-
ture dendritic cells. J Immunol. 2002;169:1669-1675.
9. Altieri DC. Validating survivin as a cancer therapeutic target.
Nat Rev Cancer. 2003;3:46-54.0. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-
leukemia effect of donor lymphocyte transfusions in marrow
grafted patients. European Group for Blood and Marrow
Transplantation Working Party Chronic Leukemia. Blood.
1995;86:2041-2050.
1. Collins RH Jr, Shpilberg O, DrobyskiWR, et al. Donor leukocyte
infusions in 140 patients with relapsed malignancy after allogeneic
bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
2. Van Tendeloo VF, Snoeck HW, Lardon F, et al. Nonviral trans-
fection of distinct types of human dendritic cells: high-efﬁciency
gene transfer by electroporation into hematopoietic progenitor-,
but not monocyte-, derived dendritic cells.Gene Ther. 1998;5:700-
707.
3. Ueno H, Tcherepanova I, Reygrobellet O, et al. (2004) Den-
dritic cell subsets generated from CD34 hematopoietic pro-
genitors can be transfected with mRNA and induce antigen-
speciﬁc cytotoxic T cell responses. J Immunol Methods. 2004;
285:171-180.
4. Takahashi M, Narita M, Ayres F, et al. Cytoplasmic expression
of EGFP in dendritic cells transfected with in vitro transcribed
mRNA or cellular total RNA extracted from EGFP expressing
leukemia cells. Med Oncol. 2003;20:335-348.
5. Osman Y, Narita M, Ayres F, et al. Generation of Ag-speciﬁc
cytotoxic T lymphocytes by DC transfected with in vitro tran-
scribed inﬂuenza virus matrix protein (M1) mRNA. Cytotherapy.
2003;5:161-168.
6. Isambert H. Understanding the electroporation of cells and
artiﬁcial bilayer membrane. Phys Rev Lett. 1998;80:3404.
7. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of
cancer treatment using enhanced delivery of bleomycin by
electroporation. Cancer Treat Rev. 2003;29:371-387.
8. Valic B, Golzio M, Pavlin M, et al. Effect of electric ﬁeld
induced transmembrane potential on spheroidal cells: theory
and experiment. Eur Biophys J. 2003;32:519-528.
9. Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-
speciﬁc cytotoxic T lymphocytes in cancer patients by autologous
tumor RNA-transfected dendritic cells. Ann Surg. 2002;235:540-
549.
0. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell
biology. Adv Immunol. 2005;88:193-233.
1. Meyer-Wentrup F, Burdach S. Efﬁcacy of dendritic cell gen-
eration for clinical use: recovery and purity of monocytes and
mature dendritic cells after immunomagnetic sorting or adher-
ence selection of CD14 starting populations. J Hematother
Stem Cell Res. 2003;12:289-299.
2. Rice AM, Jones KL, Hart DN. DC preparations for therapy.
Cytotherapy. 2004;6:99-104.
3. Timmerman JM, Levy R. Dendritic cell vaccines for cancer
immunotherapy. Annu Rev Med. 1999;50:507-529.
4. Spisek R, Brazova J, Rozkova D, et al. Maturation of dendritic
cells by bacterial immunomodulators. Vaccine. 2004;22:2761-
2768.
5. Alejandro Lopez J, Crosbie G, Kelly C, et al. Monitoring and
isolation of blood dendritic cells from apheresis products in
healthy individuals: a platform for cancer immunotherapy.
J Immunol Methods. 2002;267:199-212.
